Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials

Por Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein, Holger N. Lode
Publicado em 2022-04-01

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Ca...

Por Sebastian Johannes Schober, Erika Hallmen, Florian Reßle, Hendrik Gassmann, Carolin Prexler, Angela Wawer, Irene von Luettichau, Ruth Ladenstein, Bernarda Kazanowska, Gustaf Ljungman, Felix Niggli, Olli Lohi, Julia Hauer, Bernd Gruhn, Thomas Klingebiel, Peter Bader, Stefan Burdach, Peter Lang, Monika Sparber-Sauer, Monika Sparber-Sauer, Ewa Koscielniak, Ewa Koscielniak, Uwe Thiel
Publicado em 2022-05-01

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)

Por Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Shifra Ash, Genevieve Laureys, Penelope Brock, Jean Marie Michon, Cormac Owens, Toby Trahair, Godfrey Chi Fung Chan, Ellen Ruud, Henrik Schroeder, Maja Beck-Popovic, Guenter Schreier, Hans Loibner, Peter Ambros, Keith Holmes, Maria Rita Castellani, Mark N. Gaze, Alberto Garaventa, Andrew D.J. Pearson, Holger N. Lode
Publicado em 2020-01-01